Using Monoclonal Antibodies to Fight H5N1 Influenza in Mice
Author Information
Author(s): Brendon J. Hanson, Adrianus C. M. Boon, Angeline P. C. Lim, Ashley Webb, Eng Eong Ooi, Richard J. Webby
Primary Institution: Defence Medical and Environmental Research Institute, DSO National Laboratories
Hypothesis
Can humanized monoclonal antibodies effectively provide prophylaxis and treatment against H5N1 influenza in mice?
Conclusion
The study demonstrates that humanized monoclonal antibodies can effectively protect mice from lethal H5N1 influenza challenges.
Supporting Evidence
- Two humanized monoclonal antibodies were identified that neutralized H5N1 viruses.
- VN04-2-huG1 provided complete protection at a lower dose compared to VN04-3-huG1.
- Therapeutic efficacy was observed even when antibodies were administered three days post-infection.
Takeaway
Scientists tested special antibodies in mice to see if they could stop a dangerous flu virus, and they found that these antibodies worked really well.
Methodology
Mice were given humanized monoclonal antibodies before and after being infected with H5N1 virus to assess protection and treatment efficacy.
Limitations
The study was conducted in mice, and results may not directly translate to humans.
Participant Demographics
C57BL/6 mice, female, aged 6-8 weeks.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website